This site is intended for Healthcare Professionals only.

Obesity fighting success fuels Novo Nordisk’s bet on gene-editing technology in pharma

Date:

Share post:

Capitalising on strong demand for its obesity therapies, Novo Nordisk‘s growing appetite for deals has fuelled a bet on a U.S. gene-editing company called Life Edit Therapeutics.

The Danish drugmaker’s collaboration with Durham, North Carolina-based Life Edit Therapeutics – owned by ElevateBio, a cell and gene therapy company in Waltham – is focused on up to seven programs for rare genetic disorders as well as cardiometabolic diseases.

At the heart of the tie-up is Life Edit’s technology, called base editing, which is designed to make precise changes to the human genome by tweaking one base – or letter – into a different one without affecting other letters.

Single-letter mistakes, called point mutations, can give rise to genetic diseases.

The Novo deal comes as the company basks in the success of its incredibly popular weight-loss drug Wegovy, for which demand has far outstripped supply.

At the heart of the tie-up is Life Edit’s technology, called base editing, which is designed to make precise changes to the human genome by tweaking one base – or letter – into a different one without affecting other letters.

Single-letter mistakes, called point mutations, can give rise to genetic diseases.

The Novo deal comes as the company basks in the success of its incredibly popular weight-loss drug Wegovy, for which demand has far outstripped supply.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Superdrug to open 25 new high street stores this year

The opening of new Superdrug stores is anticipated to generate over 500 jobs nationwide Superdrug is bolstering its physical...

New Hospital Scheme delays drain millions monthly from ‘scarce’ NHS funds, trust leaders warn

Trust leaders are calling on the next government to commit to constructing 40 new hospitals in England by...

NHS virtual wards set to slash waiting times, prevent 178k admissions in next 2 years

Under the new NHS virtual wards scheme, hospitals to be incentivised for prompt care, with 12-hour A&E target In...

Pharmacist Support: Trainee pharmacists get set to ACTNow for mental health awareness ahead of GPhC assessment

Pharmacist Support's annual mental health awareness campaign offers vital support ahead of GPhC assessment and registration transition Trainee pharmacists...